Gwenn Hansen Sells 4,111 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 4,111 shares of the business’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total value of $100,143.96. Following the transaction, the insider directly owned 117,227 shares in the company, valued at approximately $2,855,649.72. This trade represents a 3.39% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gwenn Hansen also recently made the following trade(s):

• On Wednesday, August 5th, Gwenn Hansen sold 4,356 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.00, for a total value of $108,900.00.
• On Thursday, July 30th, Gwenn Hansen sold 3,847 shares of Nurix Therapeutics stock. The stock was sold at an average price of $23.38, for a total value of $89,942.86.
• On Thursday, June 25th, Gwenn Hansen sold 5,394 shares of Nurix Therapeutics stock. The stock was sold at an average price of $20.00, for a total value of $107,880.00.

Nurix Therapeutics Trading Up 0.4%

NRIX stock opened at $25.22 on Friday. The firm has a market capitalization of $2.62 billion, a PE ratio of -7.31 and a beta of 1.79. Nurix Therapeutics, Inc. has a 1-year low of $8.19 and a 1-year high of $25.49. The business’s 50 day simple moving average is $21.11 and its 200 day simple moving average is $18.00.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Thursday, July 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.08). Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. The business had revenue of $9.04 million for the quarter, compared to analyst estimates of $15.29 million. As a group, sell-side analysts predict that Nurix Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.

Institutional Investors Weigh In On Nurix Therapeutics

A number of institutional investors have recently modified their holdings of NRIX. General Atlantic L.P. bought a new position in Nurix Therapeutics during the fourth quarter worth about $92,899,000. Vanguard Group Inc. boosted its holdings in Nurix Therapeutics by 32.5% in the 4th quarter. Vanguard Group Inc. now owns 5,949,512 shares of the company’s stock valued at $112,862,000 after purchasing an additional 1,460,736 shares during the period. Baker BROS. Advisors LP boosted its holdings in Nurix Therapeutics by 20.0% in the 4th quarter. Baker BROS. Advisors LP now owns 4,658,556 shares of the company’s stock valued at $88,373,000 after purchasing an additional 776,431 shares during the period. Flax Pond Capital LLC acquired a new position in shares of Nurix Therapeutics during the 4th quarter worth approximately $1,521,000. Finally, Perceptive Advisors LLC grew its position in shares of Nurix Therapeutics by 151.1% during the 4th quarter. Perceptive Advisors LLC now owns 3,555,877 shares of the company’s stock worth $67,455,000 after purchasing an additional 2,139,728 shares in the last quarter.

Analyst Ratings Changes

Several analysts recently commented on the stock. Jefferies Financial Group lifted their target price on shares of Nurix Therapeutics from $41.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, June 8th. Stifel Nicolaus raised their price objective on shares of Nurix Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Wall Street Zen upgraded Nurix Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, July 12th. UBS Group boosted their price objective on Nurix Therapeutics from $23.00 to $31.00 and gave the stock a “buy” rating in a report on Wednesday, July 22nd. Finally, Truist Financial upped their target price on Nurix Therapeutics from $32.00 to $34.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $34.00.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.